Preview

Healthcare

Healthcare

Advanced search

Clinical characteristics and efficacy of vaccination on severity in hospitalized patients with COVID-19 during different pandemic periods

https://doi.org/10.65249/1027-7218-2026-9-24-34

Abstract

Objective. To characterize clinical severity of COVID-19 in hospitalized patients during pandemic periods and to assess the effect of vaccination on disease course.

Materials and methods. Single-centre retrospective cohort study of 11,203 patients hospitalized with COVID-19 in 2020– 2023 (112,455 bed-days). Clinical severity was graded on a four-level respiratory failure scale: «none»; «oxygen mask/cannula»; «noninvasive ventilation» (NIV); «invasive mechanical ventilation» (IMV). Bayesian hierarchical ordinal regression was fitted with covariates: age, Elixhauser comorbidity index, vaccination, previous-day respiratory failure, pandemic day and disease days. Statistical analysis was performed with programming languages R 4.6.0 and Stan 2.38.0.

Results. The 28-day cumulative risk of respiratory failure was up to 50 % in the first wave, up to 80 % in the period of Alpha variant predominance, > 90 % (unvaccinated) and ≤ 65 % (vaccinated) in the period of Delta variant predominance, and ≤ 25 % in the Omicron. During predominance of Delta variant, the probability of NIV/IMV reached 25–30 % in older unvaccinated patients with comorbidities compared to ≤ 4.5 % in vaccinated ones; during predominance of Omicron variants it was < 1 %, though up to 20 % still required oxygen. After standardization, vaccination was associated with a lower cumulative risk from September 2021 to March 2022, peaking in December 2021: -24.3 % (95 % CI (-17,6; -30,6)).

Conclusion. Respiratory failure severity varied by pandemic period, and vaccination against SARS-CoV-2 had a protective effect in hospitalized patients.

About the Authors

D. Litvinchuk
Белорусский государственный медицинский университет
Belarus


D. Danilau
Белорусский государственный медицинский университет
Belarus


I. Karpov
Белорусский государственный медицинский университет
Belarus


References

1. WHO. WHO COVID-19 dashboard. 2026. Available at: https://data.who.int/dashboards/covid19/summary (accessed: 07.08.2026).

2. Rahimi A., Mirzazadeh A., Tavakolpour S. Genetics and genomics of SARS-CoV-2. Genom. 2021; 113(1). doi:10.1016/j.ygeno.2020.09.059.

3. Volz E., Mishra S., Chand M., et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021; 593 (7858). doi:10.1038/s41586-021-03470-x.

4. Twohig K.A., Nyberg T., Zaidi A., et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 Delta (B.1.617.2) compared with Alpha (B.1.1.7) variants of concern. Lancet Infect Dis. 2022; 22(1): 35–42.

5. Tian D., Sun Y., Xu H., Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J Med Virol. 2022; 94(6). doi:10.1002/jmv.27643.

6. Relan P., Motaze N.V., Kothari K., et al. Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages. BMJ Glob Health. 2023; 8(7). doi:10.1136/bmjgh-2023-012328.

7. Bast E., Tang F., Dahn J., Palacio A. Increased risk of hospitalisation and death with the Delta variant in the USA. Lancet Infect Dis. 2021; 21(12). doi:10.1016/S1473-3099(21)00685-X.

8. Adjei S., Hong K., Molinari N.A.M., et al. Mortality risk among patients hospitalized primarily for COVID-19 during the Omicron and Delta variant pandemic periods – United States, April 2020 – June 2022. MMWR. 2022; 71(37). doi:10.15585/mmwr.mm7137a4.

9. Dashkevich A., Kolomiets N. Characteristics of the epidemic process of COVID-19 in the Republic of Belarus. Klinicheskaya infektologiya i parazitologiya. 2024; 13(1): 70–80. (in Russian)

10. Mitchell W.B. Thromboinflammation in COVID-19 acute lung injury. Paediatr Respir Rev. 2020; 35: 20–24.

11. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine. The Lancet. 2021; 397(10275). doi:10.1016/s0140-6736(21)00234-8.

12. Rahmani K., Shavaleh R., Forouhi M., et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19. Front Public Health. 2022; 10. doi:10.3389/fpubh.2022.873596.

13. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020; 20(8). doi:10.1016/s1473-3099(20)30483-7.

14. Gasparini A. comorbidity: an R package for computing comorbidity scores. J Open Source Softw. 2018; 3(23). doi: 10.21105/joss.00648.

15. Gelman A., Carlin J.B., Stern H.S., et al. Bayesian Data Analysis. 3rd ed. Boca Raton: Chapman & Hall/CRC; 2013. 675. doi: 10.1201/b16018.

16. Rohde M.D., French B., Stewart T.G., Harrell Jr. F.E. Bayesian transition models for ordinal longitudinal outcomes. Stat Med. 2024; 43(18). doi: 10.1002/sim.10133.

17. Stan Development Team. Stan modeling language user’s guide and reference manual (Version 2.39). Available at: https://mc-stan.org (accessed: 07.08.2026).

18. Burkner P.C. Bayesian item response modeling in R with BRMS and Stan. J Stat Softw. 2021; 100(5): 1–54.

19. R Core Team. R: a language and environment for statistical computing. Vienna : R Foundation for Statistical Computing; 2026. Available at: https://www.R-project.org. (accessed: 07.08.2026).


Review

For citations:


Litvinchuk D., Danilau D., Karpov I. Clinical characteristics and efficacy of vaccination on severity in hospitalized patients with COVID-19 during different pandemic periods. Healthcare. 2026;1(9):24-34. (In Russ.) https://doi.org/10.65249/1027-7218-2026-9-24-34

Views: 149

JATS XML


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1027-7218 (Print)